Recombinant Human c-Abl Protein (GST Tag)
Beta LifeScience
SKU/CAT #: BLPSN-0500
Recombinant Human c-Abl Protein (GST Tag)
Beta LifeScience
SKU/CAT #: BLPSN-0500
Catalog No.: BLPSN-0500
Product Overview
| Tag | GST |
| Host Species | Human |
| Accession | NP_009297.2 |
| Synonym | ABL, bcr/abl, c-ABL, c-ABL1, JTK7, p150, v-abl |
| Background | c-Abl belongs to the class of tyrosine kinases and is the prototype of a subfamily which includes two members, c-Abl and Arg (Abl-related gene). Both proteins are localized at the cell membrane, actin cytoskeleton and cytosol, and c-Abl is present in the nucleus as well. c-Abl is a non-receptor tyrosine kinase that participates in multiple signaling pathways linking the cell surface, cytoskeleton, and the nucleus. Recent in vitro studies have also linked c-Abl to amyloid-beta-induced toxicity and tau phosphorylation. c-Abl has been implicated in many cellular processes including differentiation, division, adhesion, death, and stress response. c-Abl is a latent tyrosine kinase that becomes activated in response to numerous extra- and intra-cellular stimuli. The c-Abl protein is a ubiquitously expressed nonreceptor tyrosine kinase involved in the development and function of many mammalian organ systems, including the immune system and bone. It regulates the cellular response to TAM through functional interaction with the estrogen receptor, which suggests c-Abl as a therapeutic target and a prognostic tumor marker for breast cancer. c-Abl also plays a key role in signaling chemokine-induced T-cell migration. In addition, c-Abl contains NLSs (nuclear localization signals) and DNA-binding sequences important for nuclear functions. c-Abl has become an important therapeutic target in human chronic myeloid leukaemia.Immune CheckpointImmunotherapyCancer ImmunotherapyTargeted Therapy |
| Description | A DNA sequence encoding the amino acid sequence (Pro 137-Ser 554) of human ABL1 isoform B (NP_009297.2) was fused with the GST tag at the N-terminus. |
| Source | Baculovirus-Insect Cells |
| Predicted N Terminal | Met |
| AA Sequence | Pro 137-Ser 554 |
| Molecular Weight | The recombinant human ABL1/GST chimera consists of 645 a.a. and predicts a molecular mass of 74 kDa. It migrates as an approximately 65 kDa band in SDS-PAGE under reducing conditions. |
| Purity | >75% as determined by SDS-PAGE |
| Endotoxin | < 1.0 EU per μg of the protein as determined by the LAL method |
| Bioactivity | The specific activity was determined to be 240 nmol/min/mg using synthetic Abl peptide (EAIYAAPFAKKK) as substrate. |
| Formulation | Supplied as sterile 50mM Tris, 100mM NaCl, 0.5mM PMSF, 0.5mM EDTA, 0.5mM Reduced Glutathione, pH 8.0. |
| Stability | The recombinant proteins are stable for up to 1 year from date of receipt at -70°C. |
| Usage | For Research Use Only |
| Storage | Store the protein under sterile conditions at -20°C to -80°C. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
